Organon & Co. Up 10.94% To $18.15 After Earnings

Organon & Co (OGN) missed earnings projections on 2/15/2024 for Q4 2023.

reported that it broke-even during the quarter.



The stock is up 10.94% to $18.15 after the report.

Organon & Co.'s profit margins maintained as both earnings and revenue declined at the same pace.

Wall Street Analysts had an average rating of Hold on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Organon & Co. has performed a little below average during the past few months. Before the report, Organon & Co. received a Long-Term Technical Rank by InvestorsObserver of 46, putting it in the bottom half of stocks. The firm was recently trading at a 52-week low of $10.84 on December 6, 2023 and set a 52-week high on February 15, 2023 at $29.37.

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.